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Adipose tissue has the largest capacity to store energy in the body and provides
energy through the release of free fatty acids during times of energy need. Different
types of immune cells are recruited to adipose tissue under various physiological
conditions, indicating that these cells contribute to the regulation of adipose tissue.
One major pathway influenced by a number of immune cells is the release of free
fatty acids through lipolysis during both physiological (e.g., cold stress) and
pathophysiological processes (e.g., obesity, type 2 diabetes). Adipose tissue expan-
sion during obesity leads to immune cell infiltration and adipose tissue remodeling,
a homeostatic process that promotes inflammation in adipose tissue. The release of
proinflammatory cytokines stimulates lipolysis and causes insulin resistance, lead-
ing to adipose tissue dysfunction and systemic disruptions of metabolism. This
review focuses on the interactions of cytokines and other inflammatory molecules
that regulate adipose tissue lipolysis during physiological and pathophysiological
states.
adipocyte; lipolysis; cytokines
LIPOLYSIS IS THE HYDROLYSIS of triglycerides (TGs) to free fatty
acids (FFAs) and glycerol. A variety of enzymes are involved
in this process that vary depending on the cell type. In
adipocytes, lipolysis occurs via the actions of adipose tri-
glyceride lipase (ATGL), hormone-sensitive lipase (HSL),
and monoglyceride lipase (Fig. 1). The lipolytic pathway is
highly regulated by both hormonal and nutritional factors.
Stimulation of lipolysis provides FFA release from adipocytes
that is critical in times of negative energy balance, including
exercise and fasting. However, the inability to inhibit lipolysis
when FFA are not needed can have serious metabolic conse-
quences, including the development of type 2 diabetes mellitus
(T2DM). A great deal of progress on dissecting the molecular
regulation of adipose tissue lipolysis has occurred in the past
two decades and has been recently reviewed (2, 52). The
regulation of lipolysis occurs by multiple mechanisms, includ-
ing modulation of transcription and translation, posttransla-
tional modifications, cellular localization, protein-protein in-
teractions, and protein stability/degradation (2, 52). There are
many stimulators of adipocyte lipolysis, including cat-
echolamines, natriuretic peptides, growth hormone, glucocor-
ticoids, and TNF. Whereas the primary antilipolytic pathway
is regulated by insulin, the mobilization of FFAs from adipose
tissue is recognized as playing an important role in insulin
resistance and T2DM and supports the notion that dysregula-
tion of adipose tissue lipolysis is a critical factor in metabolic
disease states.
The primary source of lipolytic regulators produced in adi-
pose tissue are cytokines. Table 1 summarizes influential
cytokines that regulate adipocyte lipolysis. Enhanced adipose
tissue cytokine release during obesity drives low-grade inflam-
mation, resulting in systemic impairments of glucose and
insulin tolerance and lipid metabolism (53). However, the
metabolic response to obesity is varied, and there is a consid-
erable proportion of obese individuals that lack obesity-asso-
ciated disease and are metabolically healthy (57). Recent
studies implicate lipid storage, extracellular matrix composi-
tion, and inflammation as factors that distinguish metabolically
healthy from metabolically unhealthy obesity (31, 38, 47, 58).
Secretion of cytokines from immune cells in adipose tissue
appears to be a key component linking inflammation, lipid
storage, unregulated lipolysis, ectopic fat and metabolic dis-
ease through both paracrine and endocrine mechanisms (42).
Storage of lipids in adipose tissue protects against the devel-
opment of metabolic disease (33), while the inability to store
lipids in adipose tissue redistributes body fat leading to ectopic
storage and metabolic impairment (6). This review will focus
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on how cytokines influence adipocyte lipolysis and how this
relates to the development of insulin resistance and obesity
associated comorbidities.
Tumor Necrosis Factor--Stimulated Lipolysis
Tumor necrosis factor- (TNF) was the first cytokine
shown to be produced in adipose tissue and increased in
conditions of obesity and insulin resistance (28). TNF is a
potent mediator of adipose tissue and systemic insulin resis-
tance (28). TNF induces insulin resistance through multiple
mechanisms that include inhibition of adipogenesis (81); inhi-
bition of insulin-sensitive glucose uptake in mature adipocytes
(27); inhibition of glucose transporter 4 (GLUT4) (76), insulin
receptor (IR), and insulin receptor substrate-1 (IRS-1) expres-
sion (75); and the ability to alter IR and IRS-1 phosphorylation
(27). Accordingly, animals that lack TNF (26) have improved
systemic insulin sensitivity and glucose tolerance. TNF sig-
nals through TNF receptors (TNFR)1 and -2 and leads to
transcriptional changes mediated through activation of nuclear
factor-B (NF-B) and extracellular signal-related kinase
(ERK) signaling (Figs. 1 and 2). Mice that lack TNFR1 and -2
























Fig. 1. TNF signaling shapes lipid metabo-
lism. Signaling of TNF through TNFR1 leads
to activation of multiple signaling pathways
including NF-B and ERKs. Activation of
these pathways leads to transcriptional
changes resulting in reduced expression of
lipoprotein lipase. TNF signaling induces a
loss of the lipid droplet protein perilipin and
activation of adipose triglyceride lipase
(ATGL) and hormone-sensitive lipase (HSL).
These enzymes act on triacylglycerol (TAG)
and diacylglycerol (DAG), resulting in the re-
lease of free fatty acids (FA). To further pro-
mote lipolysis, TNF activates proteasome-
dependent degradation of Gi proteins that have
the ability to reduce antilipolytic adenosine
signaling.
Table 1. Influence of cytokines on lipolysis
Symbol Cytokine Name Model Effect on Lipolysis References
TNF Tumor necrosis factor  Rat adipocytes, human adipocytes, 3T3-L1 adipocytes 1 16, 17, 41, 71
IL-1/IL-1 Interleukin-1 ( and ) 3T3-F442A adipocytes, 3T3-L1 adipocytes 1 11, 60
IL-18 Interleukin-18 Not studied % or 2 (prediction)
IL-6 Interleukin-6 3T3-L1 adipocytes 1 30, 56
LIF Leukemia inhibitory factor 3T3-F442A adipocytes, 3T3-L1 adipocytes 1 48
OSM Oncostatin M Not studied 1 (prediction)
CNTF Ciliary neurotrophic factor 3T3-L1 adipocytes % 5
CT-1 Cardiotrophin 1 Mouse adipocytes, 3T3-L1 adipocytes % or 1 44, 49
IL-4 Interleukin-4 3T3-L1 adipocytes 1 (direct or indirect?) 51, 82
IL-10 Interleukin-10 Not directly studied 2 (indirect) 45
IL-15 Interleukin-15 Porcine adipocytes 1 1
IL-17a Interleukin-17a Human adipocytes 1 70
IL-21 Interleukin-21 3T3-L1 adipocytes 2 (indirect) 8
IFN Interferon- 3T3-F422A adipocytes 1 11
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(85). In both human and murine adipocytes, signaling through
TNFR1 appears to have the largest contribution to insulin
resistance (55, 90).
Adipose tissue macrophages (ATMs) produce the majority
of TNF in adipose tissue (93). It has been known for over a
decade that adipose tissue expression of TNF increases with
macrophage number and is associated with the development of
insulin resistance (25, 79). ATMs increase acutely during times
of lipolysis, including fasting and pharmacological activation
(37). During a weight loss time course in diet-induced obese
C57BL/6 mice, ATMs are reduced by day 21 and continue to
decrease until day 60 (37). Interestingly, over this same time
course, tissue TNF levels are not reduced, as would be
expected with decreased ATMs (37). Whether TNF expres-
sion is increased at the level of gene expression, or a different
cell type is contributing to the maintenance of TNF expres-
sion, is not known. However, it is well established that TNF
reduces lipoprotein lipase (LPL) expression in adipocytes (32).
The coupling of reduced LPL expression and lipolysis may be
necessary for fat pad contraction during weight loss. It is
unknown whether the expressions of TNF and proinflamma-
tory cytokines in adipose tissue revert to that of lean phenotype
after prolonged weight loss. Future studies will likely investi-
gate the impact of inflammatory cytokines on subsequent
weight cycling and lipid distribution.
In addition to prominent effects on insulin sensitivity and
LPL in adipocytes, TNF also alters adipocyte metabolism
through the induction of lipolysis in many species including
humans (16–18, 65, 71, 73, 97). Unlike the acute effects of
-adrenergic signaling-induced lipolysis, TNF-induced lipol-
ysis occurs 3 h after treatment, indicating a transcription-
dependent mechanism (96). Multiple mechanisms have been
demonstrated to play a role in TNF-induced lipolysis, includ-
ing intracellular signaling cascades, metabolites, and lipid
droplet-associated proteins (Fig. 1). Both ATGL and HSL
contribute to TNF-induced lipolysis (96). To achieve maxi-
mal lipolysis in response to TNF, the ATGL-regulating pro-
tein comparative gene identification 58 is required and expres-
sion of the inhibitory protein G0/G1 switch 2 must be decreased
in 3T3-L1 adipocytes (96). Treatment of adipocytes with
TNF activates ERK signaling pathways, and blocking ERK
activation results in a reduction of lipolysis in primary human
adipocyte and 3T3-L1 adipocytes (72, 97). ERK inhibition is
also associated with a TNF-induced reduction of the lipid
droplet-associated protein perilipin 1 (97). In primary human
adipocytes, inhibition of NF-B subunit p65 nuclear translo-
cation results in a reduction of glycerol release in response to
TNF (41). Interestingly, in addition to reducing lipolysis, the
combination of TNF and NF-B inhibition resulted in a
significant decrease of perilipin and HSL gene and protein
expression, but did not alter ATGL gene expression (41).
Metabolites also play a role in regulating lipolysis. Adeno-
sine reduces lipolysis through activation of Gi proteins that
inhibit adenylyl cyclase (Fig. 1) (24). In primary rat adi-
pocytes, TNF reduces Gi proteins in a proteasome dependent
manner (3, 16) that results in a loss of inhibitory signaling
through the adenosine A1 receptors and enhanced lipolysis. In
3T3-L1 adipocytes, the lipolytic effects of TNF require glu-
cose and lipolysis increases with greater concentrations of
glucose in the cell culture media (18). Additionally, this effect
of glucose is specific to sugars that can support lactate produc-
tion. Like glucose, mannose also supports higher rates of
glycerol release and release of lactate from adipocytes,
whereas sugars that do not support lactate formation (galactose
and fructose) limit TNF-induced glycerol release (18). Con-
sistent with the previous observations, inhibition of glycolysis
inhibits glycerol release in response to TNF (18). Phosphor-
ylation of ERKs in response to TNF occurs in both the
presence and the absence of glucose, and a decrease in perilipin
occurs in the presence and absence of glucose (18). These data
indicate that metabolites produced by glycolysis support lipol-















Fig. 2. Lipolysis cytokines and signaling pro-
teins. Adipose tissue produces a variety of
cytokines that can activate lipolysis in adi-
pocytes. In addition to cytokines, pathogen-
associated molecular patterns can activate
adipocyte lipolysis. These cytokines bind to
specific receptors and activate signaling
pathways that contribute to lipolysis. Pre-
sented are the cytokines, receptors, and con-
ical signaling pathways that contribute to
lipolysis. LIF, leukemia inhibitory factor;
OSM, oncostatin M; NOD, nucleotide-
binding oligomerization domain-containing
protein; TLR, Toll-like receptor.
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these findings remain unknown. It is interesting to note that the
induction of lipolysis via -adrenergic receptors does not
require glucose (18). Collectively, these studies indicate that
the NF-B and ERK signaling pathways as well as glucose
metabolism contribute to TNF-induced lipolysis. Interest-
ingly, coculture of macrophages with 3T3-L1 adipocytes
causes increased basal glucose uptake in 3T3-L1 adipocytes,
increased GLUT1 protein content, and insulin resistance (46).
This insulin resistance is significantly rescued by antibody-
mediated TNF depletion (46). Currently, the effects of TNF-
targeted therapies on lipolysis have not been studied in clinical
trials. However, with the increased use of these medications for
inflammatory conditions, there may be potential to examine
their effects. The influence of TNF on lipolysis has been
demonstrated across multiple cell lines, but the importance of
each pathway is not known and likely varies depending on the
type and/or source of adipocytes. Integration of these pathways
is needed to understand the acute regulation of TNF-induced
lipolysis and how it is linked to substrate metabolism.
Interleukin-1, Interleukin-1, Interleukin-18
The secretion of both interleukin (IL)-1 and IL-18 is
regulated by caspase-1 (68). In the obese condition, activation
of the nucleotide-binding oligomerization domain-like recep-
tor, pyrin domain-containing (NLRP3) inflammasome regu-
lates caspase-1 activation to influence the synthesis of IL-1
and IL-18 (88). The NLRP3 inflammasome is activated in
response to metabolic danger signals (e.g., ceramides, fatty
acids, and hyperglycemia) and thus plays an important role in
linking impairments of metabolism during obesity and T2DM
with cytokine secretion and insulin resistance (88, 94, 99).
Knockout of the NLRP3 inflammasome reduces adipose tissue
inflammation during diet-induced obesity and leads to im-
provements in insulin sensitivity in skeletal muscle, liver, and
adipose tissue (78, 88, 94). Although the NLRP3 inflam-
masome is primarily expressed in macrophages and dendritic
cells, its components are present in adipocytes (19). Caspase-
1/ and NLRP3/ adipocytes have increased capacity to
store lipids and increased expression of GLUT4, adiponectin,
and peroxisome proliferator-activated receptor- (PPAR),
which are associated with improved adipose tissue function
(77). The NLRP3 inflammasome and caspase-1 influence adi-
pogenesis and the storage of lipids in adipocytes; however, the
in vivo function of adipocyte-expressed NLRP3 and its con-
tribution to insulin sensitivity have not been investigated.
Initial studies using recombinant IL-1 demonstrated its abil-
ity to increase lipolytic activity in adipocytes (11, 60). More
recently, studies in mouse and human primary adipocytes
showed that IL-1 represses adipogenesis and decreases the
expression of PPAR, adiponectin, and GLUT4 (39, 77). In
response to chronic treatment with IL-1, mouse 3T3-L1 and
3T3-F442A and human adipocytes have reduced phosphoryla-
tion of IR, IRS-1, protein kinase B (Akt), and ERK1/2 in a
dose-dependent manner (39, 77). Along with changes in insulin
signaling, IL-1 also increases the basal rate of lipolysis in
3T3-L1 but not 3T3-F442A adipocytes (39). IL-1 is known to
have similar effects on insulin resistance (21). IL-1 and -
signal through IL-1 receptor 1, whose activation results in
NK-B-dependent transcription (Fig. 2). Mice that lack IL-1
receptor 1 are protected against inflammation associated with
diet-induced obesity and have improved glucose tolerance. The
effects induced by IL-1 and IL-1 may be in part mediated by
their ability to induce IL-6 expression and subsequently signal
transducer and activator of transcription 3 (STAT3) activation,
which are known to contribute to lipolysis (13, 84). Unlike
IL-1 and IL-1, IL-18 does not influence adipogenesis or
appear to cause insulin resistance in adipocytes (77). IL-18
modestly enhances insulin-stimulated glucose uptake and mod-
estly counteracts the reduction of insulin-stimulated glucose
uptake induced by TNF in 3T3-L1 adipocytes (89). Yet, there
is also evidence that IL-18 suppresses adiponectin gene ex-
pression and secretion in cultured mouse adipocytes (4). It is
likely that IL-18 does not share the lipolytic properties of
IL-1 and IL-1, since mice that lack IL-18 develop obesity
and insulin resistance due to hyperphagia (50). There is grow-
ing interest in IL-1-targeted therapies for the management of
inflammatory disease. Interestingly, glyburide, an insulin
secretagogue, is also an inhibitor of inflammasome activation
(40). It appears to have anti-inflammatory effects in addition to
its ability to increase insulin secretion and lower blood glucose,
TGs, and FFAs. The contributions of inflammasome inhibition
versus effects on insulin secretion have not been examined.
Anakinra, an IL-1 receptor antagonist, has been shown to
enhance insulin secretion and lower HbA1C; however, it has
minimal effects on TGs and blood cholesterol (40). Thus,
IL-1 and IL-1 and IL-18 appear to have divergent metabolic
effects that merit further study to determine the impact of
inflammasome activation on adipocytes and adipose tissue.
Glycoprotein 130 Cytokines
The IL-6 family of cytokines is a group of functionally and
structurally related proteins that consist of IL-6, IL-11, IL-27,
leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary
neurotrophic factor (CNTF), cardiotrophin-1 (CT-1), car-
diotrophin-like cytokine (CLC), and neuropoietin (NP) (22).
These cytokines regulate a variety of complex biological pro-
cesses. Because all IL-6 family members utilize glycoprotein
130 (gp130) receptor and it is required for signaling, the IL-6
family is commonly referred to as gp130 cytokines (10). IL-6
family cytokines utilize gp130 and other receptor proteins,
including the oncostatin receptor and LIF receptor. Once acti-
vated, signaling by gp130 family members causes STAT3
translocation to the nucleus and STAT3-dependent transcrip-
tion (Fig. 2). It is well known that IL-6 concentrations are
increased in adipose tissue, and circulating levels are associ-
ated with metabolic impairments during obesity and T2DM
(59, 91). However, IL-6 levels are also increased during
exercise and may contribute to some of the beneficial effects of
physical activity on health (54). A study in humans demon-
strated that IL-6, at concentrations that do not affect cat-
echolamines or TNF, induces lipolysis and enhances fatty
acid oxidation (87). In older adults, IL-6 increased the rate of
appearance of FFAs as well as fatty acid disposal, further
confirming an in vivo effect of IL-6 on adipose tissue lipolysis
and fatty acid oxidation in humans (56). Mouse models of IL-6
deletion have generated contradictory data. It has been reported
that IL-6/ mice develop mature-onset obesity (92), whereas
others have not observed this effect (7). Treatment of 3T3-L1
adipocytes with IL-6 increases glycerol and NEFA release.
However, there is variation in the degree of magnitude ob-
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served across studies (30, 56). Also, IL-6-induced lipolysis
appears to be influenced by other hormonal factors. The com-
bined treatment of dexamethasone and growth hormone is
capable of inhibiting IL-6-induced lipolysis (56). It is notewor-
thy that the in vivo changes in lipolysis and lipid oxidation in
humans can be mimicked in cell culture models. In addition to
the lipolytic actions observed in adipocytes, treatment of L6
myotubes with IL-6 increases palmitate oxidation (56). A role
for IL-6 in energy expenditure was demonstrated in IL-6/
mice under cold stress. IL-6/ mice have reduced energy
expenditure under basal conditions and when challenged with
cold stress have a reduced ability to maintain core temperature
(95). It is interesting that uncoupling protein-1 (UCP1) expres-
sion in brown adipose tissue was not different in wild-type
(WT) and IL-6/ mice, indicating a capacity for thermogen-
esis; however, it may be that the delivery of substrates to the
tissue was reduced. The contribution of IL-6 to cold-induced
lipolysis in white adipose tissue for sustaining energy produc-
tion during cold-induced thermogenesis has not been ad-
dressed.
Although the effects of IL-6 on lipolysis have been studied,
it is only one member of the larger gp130 cytokine family, and
the effects of other cytokine members of this family on adipose
tissue lipolysis have not been well studied. LIF modifies
adipocyte lipid metabolism by reducing LPL activity, slightly
increasing lipogenesis and modestly increasing lipolysis in
cultured murine adipocytes (48). CT-1 has recently been
shown to be important in the control of glucose homeostasis
and metabolism, as mice that lack CT-1 have reduced energy
expenditure and increased body weight (49). CT-1/ mice
have reduced expression of ATGL and HSL in adipose tissue
at 12 mo of age and increased basal lipolysis. However, when
adipocytes were isolated from 2-mo-old WT and CT-1/
mice, there were no differences in basal lipolysis, indicating
that changes in adipocyte lipolysis were secondary to weight
gain (49). Delivery of recombinant CT-1 (0.2 mg·kg1·day1)
to ob/ob mice for 10 days was shown to enhance glycerol
release compared with pair-fed mice. Recombinant CT-1 acti-
vates lipolysis in 3T3-L1 adipocytes (44). CNTF remodels
adipocyte metabolism by promoting mitochondrial biogenesis
and reducing fatty acid esterification and lipogenesis; however,
it had no effects on lipolysis (5). In general, the effects of
gp130 cytokines on lipolysis have received minimal inves-
tigation. Hopefully, future studies will address the effects of
this family of cytokines on adipocyte lipolysis, as one of
these cytokines, OSM, is produced in immune cells in
adipose tissue and is highly regulated in mouse and human
obesity and T2DM (66).
Pattern Recognition Receptors
The systemic response to pattern-associated molecular pat-
terns (PAMPs) found on pathogens, including bacteria, viruses,
and fungi, is characterized by the mobilization of energy
resources including glucose and fatty acids. Toll-like receptors
(TLRs) are one class of pattern recognition receptors, and
human adipose tissue as a whole expresses most TLRs (36).
However, 3T3-L1 adipocytes are responsive only to TLR1,
TLR3, TLR4, and TLR2/6 agonists but not TLR5 agonists
(36). Stimulation of adipocytes with lipopolysaccharide (LPS)
causes nuclear translocation of NF-B and associated changes
in NF-B-responsive genes (36). Specifically, TLR ligand
stimulation results in enhanced gene expression and secretion
of cytokines and chemokines from adipocytes, and both c-Jun
NH2-terminal kinase and mitogen-activated protein kinase sig-
naling pathways regulate this process (35). Interestingly, the
stage of adipocyte development influences the response to
stimulation with TLR ligands (36). Preadipocytes exhibit the
highest secretion of IL-6, while mature adipocytes exhibit the
highest monocyte chemoattractant protein-1 (MCP-1) secre-
tion. Adipocytes generated from human bone marrow mesen-
chymal stem cells express TLR1-10 (14). Similarly to 3T3-L1
adipocytes, adipocytes derived from mesenchymal stem cells
are responsive to TLR1-4 and TLR6 agonists (14). However,
these cells are also responsive to TLR5 agonists and do not
respond to TLR7-9 agonists (14). Lipolysis measured by glyc-
erol release is induced in these cells by the danger-associated
molecular patterns poly(I:C) that signals through TLR3, and
LPS. Interestingly, both poly(I:C) and LPS had a comparable
induction of lipolysis (14). Adipocytes appear very responsive
to TLR3 and TLR4 stimulation, yet it is not known whether
other TLR activators would produce a comparative lipolytic
response. Because there is variation in the gene expression
response to these stimuli, there also are likely variations in the
physiological responses.
In addition to the TLRs, nucleotide-binding oligomerization
domain-containing protein (NOD)1 and -2 are also expressed
in adipocytes. NOD1 and NOD2 expression is increased during
adipogenesis in 3T3-L1 and primary human cells (29). Acti-
vation of NOD1 suppresses adipocyte differentiation and ex-
pression of PPAR, CCAAT/enhancer binding protein-, fatty
acid binding protein-4, and leptin in a dose-dependent manner
(29). NOD2 does not suppresses adipocyte differentiation in
3T3-L1 adipocytes, but it does suppress differentiation of
adipose-derived adult stem cells, indicating some possible
species-specific effects (29). NOD1 activation results in in-
creased NF-B activity, and the expression and secretion of
MCP-1 and RANTES (regulated on activation, normal T cell
expressed and secreted) from 3T3-L1 adipocytes (98). Simi-
larly, glycerol and FFA release is increased in response to
NOD1 agonists (61). The lipolytic actions of NOD1 agonist are
dependent on NF-B, protein kinase A, and HSL (61). In
human primary adipocytes, the same trend of increased MCP-1
and IL-6 expression is observed (98). Interestingly, NOD1/
2/ mice have reduced gonadal adipose tissue mass, im-
proved insulin sensitivity, and reduced adipocyte size and liver
lipid accumulation during high-fat feeding (67). Systemic ad-
ministration of NOD1 ligand (FK156) during hyperinsuline-
mic-euglycemic clamp studies in mice results in a reduced rate
of glucose infusion and reduced glucose disposal, whereas the
NOD2 ligand muramyl dipeptide had only modest effects (67).
The role of the adipocyte as a participant in the response to
innate immune activators is ambiguous. However, it is obvious
that there is a lipolytic response to both proinflammatory
cytokines and pathogen-associated molecular patterns in adi-
pocytes. It is intriguing that in addition to a significant lipolytic
response in adipocytes there is also a global remodeling of lipid
metabolism during infection. In the liver, these proinflamma-
tory signals can shift metabolism toward fatty acid synthesis
and away from fatty acid oxidation and ketogenesis (34).
Lipoproteins, including very-low-density lipoprotein (VLDL),
low-density lipoprotein, and high-density lipoprotein, can bind
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LPS, and this occurs in both the lipid and protein fractions of
lipoproteins (34). The extent to which adipose tissue lipolysis
contributes to the formation of VLDL and subsequent neutral-
ization of pathogens is not known. Adipose tissue-derived lipid
substrate may also influence the metabolism of immune cells.
Cells that regulate inflammation, particularly regulatory T cells
and M2-polarized macrophages, rely on fatty acid oxidation
(69, 89). Thus, the lipids released from adipose tissue could
support the metabolism of these cells and the resolution of
inflammation. In addition to the metabolites secreted by adi-
pose tissue, there are also a variety of adipokines that have
endocrine functions. Mice that lack adiponectin have an exag-
gerated inflammatory response to systemic LPS administration
(80), and mice that lack leptin have increased mortality in
response to sepsis (9). These studies demonstrate that adipo-
kines have the potential to influence the systemic inflammatory
response (9). Adipose tissue constitutes a large portion of body
mass and is an immunologically active compartment. Thiazo-
lidinediones (TZDs) are a unique class of insulin-sensitizing
drugs that increase adipogenesis and lipid storage in adipose
tissue and reduce lipolysis. They have also been shown to have
anti-inflammatory effects during sepsis. Yet, it is not known
whether adipocytes contribute to the beneficial effects of TZDs
through adiponectin secretion. Also, many of the anti-inflam-
matory actions attributed to TZDs may be due to their effects
on leukocytes (12, 20, 63). Future research will be needed to
assess the contribution of adipose tissue to the systemic in-
flammatory response and distinguish the metabolic influence of
adipose tissue on inflammation from its hormonal influence
upon systemic inflammatory responses.
Alternatively Activated Macrophages
Although proinflammatory cytokines and pattern recogni-
tion receptors have the ability to induce insulin resistance and
adipose tissue lipolysis, anti-inflammatory cytokines play a
role in regulating lipolysis as well. Lipolysis is necessary to
fuel thermogenesis in order to maintain body temperature
during cold exposure. Most research on thermogenesis has
focused on modulation by the central nervous system; how-
ever, recent evidence indicates that alternatively activated
macrophages play a role in this process. It is well established
that IL-4 and IL-13 are linked to the alternative activation of
macrophages and signal via STAT6 (86). IL-4 signals through
the IL-4 receptor, resulting in translocation of STAT6 to the
nucleus and STAT6-dependent gene transcription (Fig. 2).
STAT6/ mice are resistant to the development of obesity
despite developing insulin resistance and glucose intolerance
(64). Recent observations indicate that mice lacking IL-4
receptors on macrophages have a reduced ability to maintain
core body temperature in response to a cold stimulus (51).
These experiments also suggest that these cytokines do not act
directly on adipocytes, but that catecholamine production by
ATMs supports the lipolysis that is required for thermogenesis
(51). However, others have reported direct effects of IL-4 on
3T3-L1 adipocytes to inhibit adipogenesis and increase lipol-
ysis (82). Future studies will be needed to identify and under-
stand the primary targets of IL-4 in adipose tissue. It is
interesting that both proinflammatory and anti-inflammatory
signals have the capacity to influence lipolysis in adipocytes
and adipose tissue. An important discriminator of these signals
is the stimuli that activate them. The IL-4 macrophage cate-
cholamine pathway is responsive to cold stimuli and is neces-
sary for the maintenance of core body temperature. The pro-
inflammatory pathway is responsive to adipose tissue and
systemic inflammation, which may proceed in a chronic fash-
ion and may not be coupled to the increased oxidative capacity
associated with thermogenesis.
Although IL-10 is frequently used as a measure of adipose
tissue inflammatory balance, this cytokine has received a very
limited amount of attention for its potential role in adipocyte
regulation. IL-10 is known to inhibit the actions of TNF on
insulin resistance and improve insulin signaling in cultured
3T3-L1 adipocytes (45). Similarly, IL-10 inhibits NF-B acti-
vation in response to LPS (43). Its role in lipolysis may be as
a negative regulator of lipolytic signaling by inflammatory
stimuli rather than having direct effects. IL-10 signaling occurs
through the IL-10 receptor, and, like gp130 cytokines, activates
STAT3 (Fig. 2). In some circumstances, STAT3 activation
appears to have proinflammatory effects on adipocytes. How-
ever, STAT3 regulation is complex, and it will be critical to
determine how different signaling pathways determine the
specificity of STAT3 activation. In primary human adipocytes,
there is no STAT3 activation in response to IL-10, indicating
that there may be species-specific differences in IL-10 signal-
ing (83).
Metabolic Flexibility and Adipose Tissue Lipolysis
Obesity is a multifactorial disease associated with predispo-
sition of many related comorbidities. It has been noted that
healthy individuals display metabolic flexibility, with a respi-
ratory quotient that increases in response to meals (indicating
carbohydrate utilization as a fuel source) and decreases in
response to fasting (indicating fatty acid oxidation as a fuel
source). With the development of insulin resistance and
T2DM, there is a loss of metabolic flexibility that is charac-
terized by a respiratory quotient that has a reduced magnitude
of change in response to fasting or meals (15). Loss of
metabolic flexibility is accompanied by alterations in adipose
tissue lipolysis (74). Increased lipolysis also occurs with in-
creased expression of immune cell markers and proinflamma-
tory cytokines in adipose tissue (74). These conditions are also
associated with the deposition of ectopic fat in skeletal muscle
and liver. NEFA themselves cause insulin resistance in skeletal
muscle and can do so acutely after 2–3 days of fasting (23).
Thus, strategies to control lipolysis, including pharmaceuticals
directly targeted to proinflammatory cytokines (IL-1, TNF,
etc.) that enhance fat storage and adipogenesis or that couple
fatty acid oxidation to lipolysis, would be of benefit for the
management of obesity and metabolic syndrome. In addition to
adipose tissue inflammation, bacterial PAMPs from the gut
microbiota may contribute to this process as well, because type
2 diabetics are known to have increased circulating levels of
LPS (62). Modification of the gut microbiota may be an
additional way to manage lipolysis and metabolic impairments
during obesity.
Conclusions
With an increased understanding of the connections between
immune cell function and metabolic homeostasis, it is impor-
tant to understand how both cytokines and pathogen-associated
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molecular patterns affect adipocyte metabolism in order to
understand the contribution of adipose tissue to acute and
chronic inflammation. A growing body of literature in this area
has demonstrated both pro- and antilipolytic effects of im-
mune-related cytokines. The complex microenvironment of
adipose tissue means that multiple cellular targets are present
for each cytokine. Hence, cytokines are not acting singularly,
and there is potential for adipocyte-secreted proteins to impact
the production of proinflammatory cytokines. Thus, there re-
mains much to be investigated in terms of production of
cytokines, combinatorial effects on adipocytes, and cross-talk
between adipocytes, leukocytes, and other adipose tissue cells
on the influence of adipose tissue lipolysis and inflammation.
As a metabolically active tissue, adipose tissue is able to
modify systemic metabolism through the provisioning of lipids
and via the endocrine actions of adipokines. Free fatty acids
released from adipose tissue are a fuel source during times of
energy scarcity and high energy demands including exercise
and cold exposure. Dysregulation of the control of lipolysis
during metabolic disease contributes to dyslipidemia and the
deposition of ectopic fat that impairs tissue function. The
secretion of cytokines by leukocytes in adipose tissue regulates
lipolysis in both physiological and pathophysiological condi-
tions. These immunometabolic interactions have profound ef-
fects on lipolysis and present an opportunity to understand the
underlying biology controlling lipolysis and pathological lipid
metabolism during obesity and T2DM.
ACKNOWLEDGMENTS
We thank Ann Liu for assistance with figure preparation and design.
DISCLOSURES
No conflicts of interest, financial or otherwise, are declared by the author(s).
AUTHOR CONTRIBUTIONS
Author contributions: R.W.G. prepared figures; R.W.G. drafted manuscript;
R.W.G. and J.M.S. edited and revised manuscript; J.M.S. approved final
version of manuscript.
REFERENCES
1. Ajuwon KM, Spurlock ME. Direct regulation of lipolysis by interleu-
kin-15 in primary pig adipocytes. Am J Physiol Regul Integr Comp Physiol
287: R608–R611, 2004.
2. Arner P, Langin D. Lipolysis in lipid turnover, cancer cachexia, and
obesity-induced insulin resistance. Trends Endocrinol Metab 25: 255–262,
2014.
3. Botion LM, Brasier AR, Tian B, Udupi V, Green A. Inhibition of
proteasome activity blocks the ability of TNF alpha to down-regulate G(i)
proteins and stimulate lipolysis. Endocrinology 142: 5069–5075, 2001.
4. Chandrasekar B, Patel DN, Mummidi S, Kim JW, Clark RA, Valente
AJ. Interleukin-18 suppresses adiponectin expression in 3T3-L1 adi-
pocytes via a novel signal transduction pathway involving ERK1/2-
dependent NFATc4 phosphorylation. J Biol Chem 283: 4200–4209, 2008.
5. Crowe S, Turpin SM, Ke F, Kemp BE, Watt MJ. Metabolic remodeling
in adipocytes promotes ciliary neurotrophic factor-mediated fat loss in
obesity. Endocrinology 149: 2546–2556, 2008.
6. Danforth E Jr. Failure of adipocyte differentiation causes type II diabetes
mellitus? Nat Genet 26: 13, 2000.
7. Di Gregorio GB, Hensley L, Lu T, Ranganathan G, Kern PA. Lipid
and carbohydrate metabolism in mice with a targeted mutation in the IL-6
gene: absence of development of age-related obesity. Am J Physiol
Endocrinol Metab 287: E182–E187, 2004.
8. Fabrizi M, Marchetti V, Mavilio M, Marino A, Casagrande V, Cav-
alera M, Moreno-Navarrete JM, Mezza T, Sorice GP, Fiorentino L,
Menghini R, Lauro R, Monteleone G, Giaccari A, Fernandez Real
JM, Federici M. IL-21 is a major negative regulator of IRF4-dependent
lipolysis affecting Tregs in adipose tissue and systemic insulin sensitivity.
Diabetes 63: 2086–2096, 2014.
9. Faggioni R, Fantuzzi G, Gabay C, Moser A, Dinarello CA, Feingold
KR, Grunfeld C. Leptin deficiency enhances sensitivity to endotoxin-
induced lethality. Am J Physiol Regul Integr Comp Physiol 276: R136–
R142, 1999.
10. Fasnacht N, Muller W. Conditional gp130 deficient mouse mutants.
Semin Cell Dev Biol 19: 379–384, 2008.
11. Feingold KR, Doerrler W, Dinarello CA, Fiers W, Grunfeld C.
Stimulation of lipolysis in cultured fat cells by tumor necrosis factor,
interleukin-1, and the interferons is blocked by inhibition of prostaglandin
synthesis. Endocrinology 130: 10–16, 1992.
12. Ferreira AE, Sisti F, Sonego F, Wang S, Filgueiras LR, Brandt S,
Serezani AP, Du H, Cunha FQ, Alves-Filho JC, Serezani CH. PPAR-
gamma/IL-10 axis inhibits MyD88 expression and ameliorates murine
polymicrobial sepsis. J Immunol 192: 2357–2365, 2014.
13. Flower L, Gray R, Pinkney J, Mohamed-Ali V. Stimulation of inter-
leukin-6 release by interleukin-1beta from isolated human adipocytes.
Cytokine 21: 32–37, 2003.
14. Franchini M, Monnais E, Seboek D, Radimerski T, Zini E, Kaufmann
K, Lutz T, Reusch C, Ackermann M, Muller B, Linscheid P. Insulin
resistance and increased lipolysis in bone marrow derived adipocytes
stimulated with agonists of Toll-like receptors. Horm Metab Res 42:
703–709, 2010.
15. Galgani JE, Moro C, Ravussin E. Metabolic flexibility and insulin
resistance. Am J Physiol Endocrinol Metab 295: E1009–E1017, 2008.
16. Gasic S, Tian B, Green A. Tumor necrosis factor alpha stimulates
lipolysis in adipocytes by decreasing Gi protein concentrations. J Biol
Chem 274: 6770–6775, 1999.
17. Green A, Dobias SB, Walters DJ, Brasier AR. Tumor necrosis factor
increases the rate of lipolysis in primary cultures of adipocytes without
altering levels of hormone-sensitive lipase. Endocrinology 134: 2581–
2588, 1994.
18. Green A, Rumberger JM, Stuart CA, Ruhoff MS. Stimulation of
lipolysis by tumor necrosis factor-alpha in 3T3-L1 adipocytes is glucose
dependent: implications for long-term regulation of lipolysis. Diabetes 53:
74–81, 2004.
19. Guarda G, Zenger M, Yazdi AS, Schroder K, Ferrero I, Menu P,
Tardivel A, Mattmann C, Tschopp J. Differential expression of NLRP3
among hematopoietic cells. J Immunol 186: 2529–2534, 2011.
20. Haraguchi G, Kosuge H, Maejima Y, Suzuki J, Imai T, Yoshida M,
Isobe M. Pioglitazone reduces systematic inflammation and improves
mortality in apolipoprotein E knockout mice with sepsis. Intensive Care
Med 34: 1304–1312, 2008.
21. He J, Usui I, Ishizuka K, Kanatani Y, Hiratani K, Iwata M, Bukhari
A, Haruta T, Sasaoka T, Kobayashi M. Interleukin-1alpha inhibits
insulin signaling with phosphorylating insulin receptor substrate-1 on
serine residues in 3T3-L1 adipocytes. Mol Endocrinol 20: 114–124, 2006.
22. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G,
Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and
its regulation. Biochem J 374: 1–20, 2003.
23. Hoeks J, van Herpen NA, Mensink M, Moonen-Kornips E, van
Beurden D, Hesselink MK, Schrauwen P. Prolonged fasting identifies
skeletal muscle mitochondrial dysfunction as consequence rather than
cause of human insulin resistance. Diabetes 59: 2117–2125, 2010.
24. Honnor RC, Dhillon GS, Londos C. cAMP-dependent protein kinase
and lipolysis in rat adipocytes. II. Definition of steady-state relationship
with lipolytic and antilipolytic modulators. J Biol Chem 260: 15130–
15138, 1985.
25. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM.
Increased adipose tissue expression of tumor necrosis factor-alpha in
human obesity and insulin resistance. J Clin Invest 95: 2409–2415, 1995.
26. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM. Reduced
tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central
role of tumor necrosis factor-alpha. J Clin Invest 94: 1543–1549, 1994.
27. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor
necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl
Acad Sci USA 91: 4854–4858, 1994.
28. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of
tumor necrosis factor-alpha: direct role in obesity-linked insulin resis-
tance. Science 259: 87–91, 1993.
29. JSP, Hu P, Burke SJ, Collier JJ, Chen J, Zhao L. The effects of NOD




AJP-Endocrinol Metab • doi:10.1152/ajpendo.00053.2015 • www.ajpendo.org
Downloaded from journals.physiology.org/journal/ajpendo at LSU Louisiana State Univ (130.039.060.163) on September 24, 2021.
30. Ji C, Chen X, Gao C, Jiao L, Wang J, Xu G, Fu H, Guo X, Zhao Y.
IL-6 induces lipolysis and mitochondrial dysfunction, but does not affect
insulin-mediated glucose transport in 3T3-L1 adipocytes. J Bioenerg
Biomembr 43: 367–375, 2011.
31. Karelis AD, Faraj M, Bastard JP, St-Pierre DH, Brochu M,
Prud’homme D, Rabasa-Lhoret R. The metabolically healthy but obese
individual presents a favorable inflammation profile. J Clin Endocrinol
Metab 90: 4145–4150, 2005.
32. Kawakami M, Murase T, Ogawa H, Ishibashi S, Mori N, Takaku F,
Shibata S. Human recombinant TNF suppresses lipoprotein lipase activity
and stimulates lipolysis in 3T3-L1 cells. J Biochem 101: 331–338, 1987.
33. Khan T, Muise ES, Iyengar P, Wang ZV, Chandalia M, Abate N,
Zhang BB, Bonaldo P, Chua S, Scherer PE. Metabolic dysregulation
and adipose tissue fibrosis: role of collagen VI. Mol Cell Biol 29:
1575–1591, 2009.
34. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH,
Feingold KR, Grunfeld C. Effects of infection and inflammation on lipid
and lipoprotein metabolism: mechanisms and consequences to the host. J
Lipid Res 45: 1169–1196, 2004.
35. Kopp A, Buechler C, Bala M, Neumeier M, Scholmerich J, Schaffler
A. Toll-like receptor ligands cause proinflammatory and prodiabetic acti-
vation of adipocytes via phosphorylation of extracellular signal-regulated
kinase and c-Jun N-terminal kinase but not interferon regulatory factor-3.
Endocrinology 151: 1097–1108, 2010.
36. Kopp A, Buechler C, Neumeier M, Weigert J, Aslanidis C, Schol-
merich J, Schaffler A. Innate immunity and adipocyte function: ligand-
specific activation of multiple Toll-like receptors modulates cytokine,
adipokine, and chemokine secretion in adipocytes. Obesity (Silver Spring)
17: 648–656, 2009.
37. Kosteli A, Sugaru E, Haemmerle G, Martin JF, Lei J, Zechner R,
Ferrante AW Jr. Weight loss and lipolysis promote a dynamic immune
response in murine adipose tissue. J Clin Invest 120: 3466–3479, 2010.
38. Koster A, Stenholm S, Alley DE, Kim LJ, Simonsick EM, Kanaya
AM, Visser M, Houston DK, Nicklas BJ, Tylavsky FA, Satterfield S,
Goodpaster BH, Ferrucci L, Harris TB. Body fat distribution and
inflammation among obese older adults with and without metabolic
syndrome. Obesity (Silver Spring) 18: 2354–2361, 2010.
39. Lagathu C, Yvan-Charvet L, Bastard JP, Maachi M, Quignard-
Boulange A, Capeau J, Caron M. Long-term treatment with interleukin-
1beta induces insulin resistance in murine and human adipocytes. Diabe-
tologia 49: 2162–2173, 2006.
40. Lamkanfi M, Mueller JL, Vitari AC, Misaghi S, Fedorova A, De-
shayes K, Lee WP, Hoffman HM, Dixit VM. Glyburide inhibits the
Cryopyrin/Nalp3 inflammasome. J Cell Biol 187: 61–70, 2009.
41. Laurencikiene J, van Harmelen V, Arvidsson Nordstrom E, Dicker A,
Blomqvist L, Naslund E, Langin D, Arner P, Ryden M. NF-kappaB is
important for TNF-alpha-induced lipolysis in human adipocytes. J Lipid
Res 48: 1069–1077, 2007.
42. Lionetti L, Mollica MP, Lombardi A, Cavaliere G, Gifuni G, Barletta
A. From chronic overnutrition to insulin resistance: the role of fat-storing
capacity and inflammation. Nutr Metab Cardiovasc Dis 19: 146–152,
2009.
43. Lira FS, Rosa JC, Pimentel GD, Seelaender M, Damaso AR, Oyama
LM, do Nascimento CO. Both adiponectin and interleukin-10 inhibit
LPS-induced activation of the NF-kappaB pathway in 3T3-L1 adipocytes.
Cytokine 57: 98–106, 2012.
44. Lopez-Yoldi M, Fernandez-Galilea M, Laiglesia LM, Larequi E,
Prieto J, Martinez JA, Bustos M, Moreno-Aliaga MJ. Cardiotrophin-1
stimulates lipolysis through the regulation of main adipose tissue lipases.
J Lipid Res 55: 2634–2643, 2014.
45. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic
switch in adipose tissue macrophage polarization. J Clin Invest 117:
175–184, 2007.
46. Lumeng CN, Deyoung SM, Saltiel AR. Macrophages block insulin
action in adipocytes by altering expression of signaling and glucose
transport proteins. Am J Physiol Endocrinol Metab 292: E166–E174,
2007.
47. Marques-Vidal P, Velho S, Waterworth D, Waeber G, von Kanel R,
Vollenweider P. The association between inflammatory biomarkers and
metabolically healthy obesity depends of the definition used. Eur J Clin
Nutr 66: 426–435, 2012.
48. Marshall MK, Doerrler W, Feingold KR, Grunfeld C. Leukemia
inhibitory factor induces changes in lipid-metabolism in cultured adi-
pocytes. Endocrinology 135: 141–147, 1994.
49. Moreno-Aliaga MJ, Romero-Lozano MA, Castano D, Prieto J, Bustos
M. Role of cardiotrophin-1 in obesity and insulin resistance. Adipocyte 1:
112–115, 2012.
50. Netea MG, Joosten LA, Lewis E, Jensen DR, Voshol PJ, Kullberg BJ,
Tack CJ, van Krieken H, Kim SH, Stalenhoef AF, van de Loo FA,
Verschueren I, Pulawa L, Akira S, Eckel RH, Dinarello CA, van den
Berg W, van der Meer JW. Deficiency of interleukin-18 in mice leads to
hyperphagia, obesity and insulin resistance. Nat Med 12: 650–656, 2006.
51. Nguyen KD, Qiu Y, Cui X, Goh YP, Mwangi J, David T, Mukundan
L, Brombacher F, Locksley RM, Chawla A. Alternatively activated
macrophages produce catecholamines to sustain adaptive thermogenesis.
Nature 480: 104–108, 2011.
52. Nielsen TS, Jessen N, Jorgensen JO, Moller N, Lund S. Dissecting
adipose tissue lipolysis: molecular regulation and implications for meta-
bolic disease. J Mol Endocrinol 52: R199–R222, 2014.
53. Osborn O, Olefsky JM. The cellular and signaling networks linking the
immune system and metabolism in disease. Nat Med 18: 363–374, 2012.
54. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal
muscle as a secretory organ. Nat Rev Endocrinol 8: 457–465, 2012.
55. Peraldi P, Hotamisligil GS, Buurman WA, White MF, Spiegelman
BM. Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through
stimulation of the p55 TNF receptor and activation of sphingomyelinase.
J Biol Chem 271: 13018–13022, 1996.
56. Petersen EW, Carey AL, Sacchetti M, Steinberg GR, Macaulay SL,
Febbraio MA, Pedersen BK. Acute IL-6 treatment increases fatty acid
turnover in elderly humans in vivo and in tissue culture in vitro. Am J
Physiol Endocrinol Metab 288: E155–E162, 2005.
57. Phillips CM. Metabolically healthy obesity: definitions, determinants and
clinical implications. Rev Endocrinol Metab Disord 14: 219–227, 2013.
58. Phillips CM, Perry IJ. Does inflammation determine metabolic health
status in obese and nonobese adults? J Clin Endocrinol Metab 98:
E1610–E1619, 2013.
59. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of
the innate immune system: association of acute-phase reactants and
interleukin-6 with metabolic syndrome X. Diabetologia 40: 1286–1292,
1997.
60. Price SR, Mizel SB, Pekala PH. Regulation of lipoprotein lipase syn-
thesis and 3T3–L1 adipocyte metabolism by recombinant interleukin 1.
Biochim Biophys Acta 889: 374–381, 1986.
61. Purohit JS, Hu P, Chen G, Whelan J, Moustaid-Moussa N, Zhao L.
Activation of nucleotide oligomerization domain containing protein 1
induces lipolysis through NF-kappaB and the lipolytic PKA activation in
3T3-L1 adipocytes. Biochem Cell Biol 91: 428–434, 2013.
62. Pussinen PJ, Havulinna AS, Lehto M, Sundvall J, Salomaa V. Endo-
toxemia is associated with an increased risk of incident diabetes. Diabetes
Care 34: 392–397, 2011.
63. Reynolds K, Novosad B, Hoffhines A, Gipson J, Johnson J, Peters J,
Gonzalez F, Gimble J, Hill M. Pretreatment with troglitazone decreases
lethality during endotoxemia in mice. J Endotoxin Res 8: 307–314, 2002.
64. Ricardo-Gonzalez RR, Red Eagle A, Odegaard JI, Jouihan H, Morel
CR, Heredia JE, Mukundan L, Wu D, Locksley RM, Chawla A.
IL-4/STAT6 immune axis regulates peripheral nutrient metabolism and
insulin sensitivity. Proc Natl Acad Sci USA 107: 22617–22622, 2010.
65. Rosenbaum SE, Greenberg AS. The short- and long-term effects of
tumor necrosis factor-alpha and BRL 49653 on peroxisome proliferator-
activated receptor (PPAR)gamma2 gene expression and other adipocyte
genes. Mol Endocrinol 12: 1150–1160, 1998.
66. Sanchez-Infantes D, White UA, Elks CM, Morrison RF, Gimble JM,
Considine RV, Ferrante AW, Ravussin E, Stephens JM. Oncostatin M
is produced in adipose tissue and is regulated in conditions of obesity and
type 2 diabetes. J Clin Endocrinol Metab jc20133555, 2013.
67. Schertzer JD, Tamrakar AK, Magalhaes JG, Pereira S, Bilan PJ,
Fullerton MD, Liu Z, Steinberg GR, Giacca A, Philpott DJ, Klip A.
NOD1 activators link innate immunity to insulin resistance. Diabetes 60:
2206–2215, 2011.
68. Schroder K, Tschopp J. The inflammasomes. Cell 140: 821–832, 2010.
69. Shi LZ, Wang R, Huang G, Vogel P, Neale G, Green DR, Chi H.
HIF1alpha-dependent glycolytic pathway orchestrates a metabolic check-
point for the differentiation of TH17 and Treg cells. J Exp Med 208:
1367–1376, 2011.
70. Shin JH, Shin DW, Noh M. Interleukin-17A inhibits adipocyte differen-
tiation in human mesenchymal stem cells and regulates pro-inflammatory
responses in adipocytes. Biochem Pharmacol 77: 1835–1844, 2009.
Review
E212 INFLAMMATION AND LIPOLYSIS
AJP-Endocrinol Metab • doi:10.1152/ajpendo.00053.2015 • www.ajpendo.org
Downloaded from journals.physiology.org/journal/ajpendo at LSU Louisiana State Univ (130.039.060.163) on September 24, 2021.
71. Souza SC, de Vargas LM, Yamamoto MT, Lien P, Franciosa MD,
Moss LG, Greenberg AS. Overexpression of perilipin A and B blocks the
ability of tumor necrosis factor alpha to increase lipolysis in 3T3–L1
adipocytes. J Biol Chem 273: 24665–24669, 1998.
72. Souza SC, Palmer HJ, Kang YH, Yamamoto MT, Muliro KV, Paulson
KE, Greenberg AS. TNF-alpha induction of lipolysis is mediated through
activation of the extracellular signal related kinase pathway in 3T3-L1
adipocytes. J Cell Biochem 89: 1077–1086, 2003.
73. Souza SC, Yamamoto MT, Franciosa MD, Lien P, Greenberg AS.
BRL 49653 blocks the lipolytic actions of tumor necrosis factor-alpha: a
potential new insulin-sensitizing mechanism for thiazolidinediones. Dia-
betes 47: 691–695, 1998.
74. Sparks LM, Ukropcova B, Smith J, Pasarica M, Hymel D, Xie H, Bray
GA, Miles JM, Smith SR. Relation of adipose tissue to metabolic
flexibility. Diabetes Res Clin Pract 83: 32–43, 2009.
75. Stephens JM, Lee J, Pilch PF. Tumor necrosis factor-alpha-induced
insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin
receptor substrate-1 and GLUT4 expression without a loss of insulin
receptor-mediated signal transduction. J Biol Chem 272: 971–976, 1997.
76. Stephens JM, Pekala PH. Transcriptional repression of the GLUT4 and
C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. J Biol
Chem 266: 21839–21845, 1991.
77. Stienstra R, Joosten LA, Koenen T, van Tits B, van Diepen JA, van
den Berg SA, Rensen PC, Voshol PJ, Fantuzzi G, Hijmans A, Kersten
S, Muller M, van den Berg WB, van Rooijen N, Wabitsch M, Kullberg
BJ, van der Meer JW, Kanneganti T, Tack CJ, Netea MG. The
inflammasome-mediated caspase-1 activation controls adipocyte differen-
tiation and insulin sensitivity. Cell Metab 12: 593–605, 2010.
78. Stienstra R, van Diepen JA, Tack CJ, Zaki MH, van de Veerdonk FL,
Perera D, Neale GA, Hooiveld GJ, Hijmans A, Vroegrijk I, van den
Berg S, Romijn J, Rensen PC, Joosten LA, Netea MG, Kanneganti
TD. Inflammasome is a central player in the induction of obesity and
insulin resistance. Proc Natl Acad Sci USA 108: 15324–15329, 2011.
79. Strissel KJ, Stancheva Z, Miyoshi H, Perfield JW, 2nd DeFuria J, Jick
Z, Greenberg AS, Obin MS. Adipocyte death, adipose tissue remodeling,
and obesity complications. Diabetes 56: 2910–2918, 2007.
80. Teoh H, Quan A, Bang KW, Wang G, Lovren F, Vu V, Haitsma JJ,
Szmitko PE, Al-Omran M, Wang CH, Gupta M, Peterson MD, Zhang
H, Chan L, Freedman J, Sweeney G, Verma S. Adiponectin deficiency
promotes endothelial activation and profoundly exacerbates sepsis-related
mortality. Am J Physiol Endocrinol Metab 295: E658–E664, 2008.
81. Torti FM, Torti SV, Larrick JW, Ringold GM. Modulation of adi-
pocyte differentiation by tumor necrosis factor and transforming growth
factor beta. J Cell Biol 108: 1105–1113, 1989.
82. Tsao CH, Shiau MY, Chuang PH, Chang YH, Hwang J. Interleukin-4
regulates lipid metabolism by inhibiting adipogenesis and promoting
lipolysis. J Lipid Res 55: 385–397, 2014.
83. Turner JJ, Foxwell KM, Kanji R, Brenner C, Wood S, Foxwell BM,
Feldmann M. Investigation of nuclear factor-kappaB inhibitors and in-
terleukin-10 as regulators of inflammatory signalling in human adipocytes.
Clin Exp Immunol 162: 487–493, 2010.
84. Uno T, He J, Usui I, Kanatani Y, Bukhari A, Fujisaka S, Yamazaki Y,
Suzuki H, Iwata M, Ishiki M, Urakaze M, Haruta T, Ogawa H,
Kobayashi M. Long-term interleukin-1alpha treatment inhibits insulin
signaling via IL-6 production and SOCS3 expression in 3T3-L1 adi-
pocytes. Horm Metab Res 40: 8–12, 2008.
85. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection
from obesity-induced insulin resistance in mice lacking TNF-alpha func-
tion. Nature 389: 610–614, 1997.
86. Van Dyken SJ, Locksley RM. Interleukin-4- and interleukin-13-mediated
alternatively activated macrophages: roles in homeostasis and disease.
Annu Rev Immunol 31: 317–343, 2013.
87. van Hall G, Steensberg A, Sacchetti M, Fischer C, Keller C, Schjerling
P, Hiscock N, Moller K, Saltin B, Febbraio MA, Pedersen BK.
Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin
Endocrinol Metab 88: 3005–3010, 2003.
88. Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K,
Mynatt RL, Ravussin E, Stephens JM, Dixit VD. The NLRP3 inflam-
masome instigates obesity-induced inflammation and insulin resistance.
Nat Med 17: 179–188, 2011.
89. Vats D, Mukundan L, Odegaard JI, Zhang L, Smith KL, Morel CR,
Wagner RA, Greaves DR, Murray PJ, Chawla A. Oxidative metabo-
lism and PGC-1beta attenuate macrophage-mediated inflammation. Cell
Metab 4: 13–24, 2006.
90. Vazquez-Carballo A, Ceperuelo-Mallafre V, Chacon MR, Maymo-
Masip E, Lorenzo M, Porras A, Vendrell J, Fernandez-Veledo S.
TWEAK prevents TNF--induced insulin resistance through PP2A acti-
vation in human adipocytes. Am J Physiol Endocrinol Metab 305: E101–
E112, 2013.
91. Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K,
Chrousos GP. Elevation of plasma cytokines in disorders of excessive
daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocri-
nol Metab 82: 1313–1316, 1997.
92. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson
SL, Ohlsson C, Jansson JO. Interleukin-6-deficient mice develop ma-
ture-onset obesity. Nat Med 8: 75–79, 2002.
93. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Fer-
rante AW Jr. Obesity is associated with macrophage accumulation in
adipose tissue. J Clin Invest 112: 1796–1808, 2003.
94. Wen H, Gris D, Lei Y, Jha S, Zhang L, Huang MT, Brickey WJ, Ting
JP. Fatty acid-induced NLRP3-ASC inflammasome activation interferes
with insulin signaling. Nat Immunol 12: 408–415, 2011.
95. Wernstedt I, Edgley A, Berndtsson A, Faldt J, Bergstrom G, Walle-
nius V, Jansson JO. Reduced stress- and cold-induced increase in energy
expenditure in interleukin-6-deficient mice. Am J Physiol Regul Integr
Comp Physiol 291: R551–R557, 2006.
96. Yang X, Zhang X, Heckmann BL, Lu X, Liu J. Relative contribution of
adipose triglyceride lipase and hormone-sensitive lipase to tumor necrosis
factor-alpha (TNF-alpha)-induced lipolysis in adipocytes. J Biol Chem
286: 40477–40485, 2011.
97. Zhang HH, Halbleib M, Ahmad F, Manganiello VC, Greenberg AS.
Tumor necrosis factor-alpha stimulates lipolysis in differentiated human
adipocytes through activation of extracellular signal-related kinase and
elevation of intracellular cAMP. Diabetes 51: 2929–2935, 2002.
98. Zhao L, Hu P, Zhou Y, Purohit J, Hwang D. NOD1 activation induces
proinflammatory gene expression and insulin resistance in 3T3-L1 adi-
pocytes. Am J Physiol Endocrinol Metab 301: E587–E598, 2011.
99. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-
interacting protein links oxidative stress to inflammasome activation. Nat
Immunol 11: 136–140, 2010.
Review
E213INFLAMMATION AND LIPOLYSIS
AJP-Endocrinol Metab • doi:10.1152/ajpendo.00053.2015 • www.ajpendo.org
Downloaded from journals.physiology.org/journal/ajpendo at LSU Louisiana State Univ (130.039.060.163) on September 24, 2021.
